Shlomo A. Koyfman

Shlomo A. Koyfman

Auto-generated profile, based on publicly available information

Shlomo A. Koyfman

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
BMBindu V. Manyam
Bindu V. Manyam
AGAdam A. Garsa
Adam A. Garsa
RCRe-I Chin
Re-I Chin
CRChandana A. Reddy
Chandana A. Reddy
BGBrian Gastman
Brian Gastman
SKShlomo A. Koyfman
Shlomo A. Koyfman

1 November 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SKShlomo A. Koyfman
Shlomo A. Koyfman
DADavid J. Adelstein
David J. Adelstein

1 August 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
BMBindu V. Manyam
Bindu V. Manyam
BGBrian Gastman
Brian Gastman
AZAlexandra Y. Zhang
Alexandra Y. Zhang
CRChandana A. Reddy
Chandana A. Reddy
BBBrian B. Burkey
Brian B. Burkey
SKShlomo A. Koyfman
Shlomo A. Koyfman

19 November 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MKMohammad K Khan
Mohammad K Khan
SKShlomo A Koyfman
Shlomo A Koyfman
GHGrant K Hunter
Grant K Hunter
CRChandana A Reddy
Chandana A Reddy
JSJerrold P Saxton
Jerrold P Saxton
To report our 20 yr experience of definitive radiotherapy for early glottic squamous cell carcinoma (SCC). Radiation records of 141 patients were retrospectively evaluated for patient, tumor, and treatment characteristics. Cox proportional hazard models were used to perform univariate (UVA) and multivariate analyses (MVA). Cause specific survival (CSS) and overall survival (OS) were plotted using cumulative incidence and Kaplan-Meir curves, respectively. Of the 91% patients that presented with impaired voice, 73% noted significant improvement. Chronic laryngeal edema and dysphagia were noted in 18% and 7%, respectively. The five year LC was 94% (T1a), 83% (T1b), 87% (T2a), 65% (T2b); the ten year LC was 89% (T1a), 83% (T1b), 87% (T2a), and 53% (T2b). The cumulative incidence of death due to larynx cancer at 10 yrs was 5.5%, respectively. On MVA, T-stage, heavy alcohol consumption during treatment, and used of weighted fields were predictive for poor outcome (p < 0.05). The five year CSS and OS was 95.9% and 76.8%, respectively. Definitive radiotherapy provides excellent LC and CSS for early glottis carcinoma, with excellent voice preservation and minimal long term toxicity. Alternative management strategies should be pursued for T2b glottis carcinomas.

15 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CKCan F. Koyuncu
Can F. Koyuncu
CLCheng Lu
Cheng Lu
KBKaustav Bera
Kaustav Bera
ZZZelin Zhang
Zelin Zhang
Jun XuJun Xu
Jun Xu
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
BACKGROUND. Patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) are potentially cured with definitive treatment. However, there are currently no reliable biomarkers of treatment failure for p16+ OPSCC. Pathologist-based visual assessment of tumor cell multinucleation (MN) has been shown to be independently prognostic of disease-free survival (DFS) in p16+ OPSCC. However, its quantification is time intensive, subjective, and at risk of interobserver variability. METHODS. We present a deep-learning–based metric, the multinucleation index (MuNI), for prognostication in p16+ OPSCC. This approach quantifies tumor MN from digitally scanned H&E-stained slides. Representative H&E-stained whole-slide images from 1094 patients with previously untreated p16+ OPSCC were acquired from 6 institutions for optimization and validation of the MuNI. RESULTS. The MuNI was prognostic for DFS, overall survival (OS), or distant metastasis–free survival (DMFS) in p16+ OPSCC, with HRs of 1.78 (95% CI: 1.37–2.30), 1.94 (1.44–2.60), and 1.88 (1.43–2.47), respectively, independent of age, smoking status, treatment type, or tumor and lymph node (T/N) categories in multivariable analyses. The MuNI was also prognostic for DFS, OS, and DMFS in patients with stage I and stage III OPSCC, separately. CONCLUSION. MuNI holds promise as a low-cost, tissue-nondestructive, H&E stain–based digital biomarker test for counseling, treatment, and surveillance of patients with p16+ OPSCC. These data support further confirmation of the MuNI in prospective trials. FUNDING. National Cancer Institute (NCI), NIH; National Institute for Biomedical Imaging and Bioengineering, NIH; National Center for Research Resources, NIH; VA Merit Review Award from the US Department of VA Biomedical Laboratory Research and Development Service; US Department of Defense (DOD) Breast Cancer Research Program Breakthrough Level 1 Award; DOD Prostate Cancer Idea Development Award; DOD Lung Cancer Investigator-Initiated Translational Research Award; DOD Peer-Reviewed Cancer Research Program; Ohio Third Frontier Technology Validation Fund; Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering; Clinical and Translational Science Award (CTSA) program, Case Western Reserve University; NCI Cancer Center Support Grant, NIH; Career Development Award from the US Department of VA Clinical Sciences Research and Development Program; Dan L. Duncan Comprehensive Cancer Center Support Grant, NIH; and Computational Genomic Epidemiology of Cancer Program, Case Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of VA, the DOD, or the US Government.

1 October 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
VVVamsi Varra
Vamsi Varra
NWNeil M. Woody
Neil M. Woody
CRChandana Reddy
Chandana Reddy
NJNikhil P. Joshi
Nikhil P. Joshi
JGJessica Geiger
Jessica Geiger
SKShlomo A. Koyfman
Shlomo A. Koyfman
Background/Aim: There are limited data regarding survival, failure patterns, and factors associated with disease recurrence in patients with cutaneous squamous cell cancer of the head and neck (cSCC-HN) with nodal metastases. Patients and Methods: A retrospective analysis of patients with cSCC-HN metastatic to cervical and/or parotid lymph nodes treated with surgery and post-operative radiation therapy was performed. Results: This study included 76 patients (57 immunocompetent and 18 immunosuppressed) with a median follow-up of 18 months. Overall survival, disease-free survival (DFS), and disease recurrence (DR) at 2 years was 60%, 49%, and 40%, respectively. Immunosuppressed patients had significantly lower 2-year DFS (28% vs. 55%; p=0.003) and higher DR (61% vs. 34%; p=0.04) compared to immunocompetent patients. Analysis of immunocompetent patients demonstrated extracapsular extension (ECE) as the only factor associated with DR (p<0.0001). Conclusion: Patients with nodal metastases from cSCC-HN have suboptimal outcomes. ECE and immunosuppression were significantly associated with DR.